BridgeBio Pharma Inc Forecast, price target & analysts
BridgeBio Pharma Inc Target price 2026 - Analyst rating & recommendation
BridgeBio Pharma Inc Classifications & Recommendation
BridgeBio Pharma Inc Price Target
| Target Price | $110.67 |
| Price | $66.91 |
| Potential |
65.40%
register free of charge
|
| Number of Estimates | 23 |
|
23 Analysts have issued a price target BridgeBio Pharma Inc 2027 .
The average BridgeBio Pharma Inc target price is $110.67.
This is
65.40%
register free of charge
$164.85
146.38%
register free of charge
$80.80
20.76%
register free of charge
|
|
| A rating was issued by 29 analysts: 26 Analysts recommend BridgeBio Pharma Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BridgeBio Pharma Inc stock has an average upside potential 2027 of
65.40%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 502.08 | 1,047.00 |
| 126.26% | 108.53% | |
| EBITDA Margin | -98.91% | -34.79% |
| 61.58% | 64.83% | |
| Net Margin | -144.39% | -50.09% |
| 40.20% | 65.31% |
25 Analysts have issued a sales forecast BridgeBio Pharma Inc 2026 . The average BridgeBio Pharma Inc sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an BridgeBio Pharma Inc EBITDA forecast 2026. The average BridgeBio Pharma Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
24 BridgeBio Pharma Inc Analysts have issued a net profit forecast 2026. The average BridgeBio Pharma Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.79 | -2.69 |
| 31.60% | 29.02% | |
| P/E | negative | |
| EV/Sales | 15.01 |
24 Analysts have issued a BridgeBio Pharma Inc forecast for earnings per share. The average BridgeBio Pharma Inc EPS is
This results in the following potential growth metrics and future valuations:
BridgeBio Pharma Inc...
Current BridgeBio Pharma Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 10 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 02 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | Sep 01 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 11 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 10 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 02 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Sep 01 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 11 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
